{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-064374","form_type":"8-K","ticker":"CADL","cik":"0001841387","company_name":"Candel Therapeutics, Inc.","filed_at":"2025-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.227242+00:00","generated_at":"2026-05-24T04:17:33.507997+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Candel reports positive final Phase 2a data for CAN-2409 in NSCLC; mOS 24.5 months, long survival tail","bullets":["mOS of 24.5 months in evaluable patients (cohort 1+2, n=46) with advanced NSCLC inadequately responding to ICI.","In patients with progressive disease at baseline (cohort 2, n=41), mOS was 21.5 months, vs. 9.8–11.8 months for docetaxel.","37% (15/41) of progressive disease patients alive >24 months; long tail of survival observed.","In non-squamous NSCLC (n=33), mOS was 25.4 months; ITT analysis showed 16.7 months vs. 9.9–12.3 months for SOC.","Systemic anti-tumor response (abscopal effect) seen in 69% of patients with multiple lesions; safety profile favorable."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-064374","json":"https://secwatch.observer/filing/0001193125-25-064374.json","markdown":"https://secwatch.observer/filing/0001193125-25-064374.md","text":"https://secwatch.observer/filing/0001193125-25-064374.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841387/000119312525064374/0001193125-25-064374-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841387/000119312525064374/d917988d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T04:17:33.507997+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}